Merus N.V. announced interim clinical data, as of a July 31, 2023 data cutoff date, from the phase 1/2 eNRGy trial and Early Access Program (EAP) of the bispecific antibody zenocutuzumab (Zeno) in patients with neuregulin 1 fusion (NRG1+) cancer presented by Principal Investigator, Dr. Alison Schram of Memorial Sloan Kettering Cancer Center at the European Society for Medical Oncology (ESMO) Congress 2023. The reported data are from the phase 1/2 eNRGy trial and EAP which are assessing the safety and anti-tumor activity of Zeno monotherapy in NRG1+ cancer.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
53.15 USD | +0.40% | -3.77% | +92.00% |
Jun. 03 | Merus Says Target Tumors in Lung Cancer Patients Decrease in Size After MCLA-129 Treatment | MT |
Jun. 03 | Truist Securities Raises Price Target on Merus to $88 From $69, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+92.00% | 3.51B | |
+15.90% | 121B | |
+13.32% | 107B | |
-3.72% | 24.82B | |
+1.48% | 22.48B | |
-9.77% | 18.32B | |
-42.28% | 16.33B | |
-17.00% | 15.31B | |
+4.74% | 14.08B | |
+26.61% | 11.74B |
- Stock Market
- Equities
- MRUS Stock
- News Merus N.V.
- Merus N.V. Announces Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer